This study is testing a new medicine called VH4524184 for treating HIV-1, a virus that attacks the immune system. They are comparing two doses of VH4524184 taken with other medications (emtricitabine and tenofovir alafenamide) to a standard treatment (dolutegravir and lamivudine). The goal is to see how well VH4524184 works over a long time and to find the best dose.

To join, you must be over 18, have never received HIV treatment, and meet certain health criteria, like having enough CD4+ T-cells, which are important for your immune system. Women must not be pregnant or breastfeeding. People with certain health conditions, such as liver issues or other infections, can't participate.

• The study requires visits to the clinic for check-ups and tests.
• Participation involves taking study medication as directed.
• There may be risks or side effects from the new medication.